PriceTargets.com logo

Hikma Pharmaceuticals - HIK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 2,436.67
  • Forecasted Upside: 22.63%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,987 As of 03/27/2025 07:56 AM ET
▼ -23 (-1.14%)

This chart shows the closing price for HIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar2,018.00Closing price on 03/26/25:
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

Analyst Price Target is GBX 2,436.67
▲ +22.63% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,436.67, with a high forecast of GBX 2,750 and a low forecast of GBX 2,000. The average price target represents a 22.63% upside from the last price of GBX 1,987.

This chart shows the closing price for HIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/261.24k1.62k2k2.37k2.75kClosing price on 03/26/25: 2,018.00High2.75kAverage2.44kLow2.00k




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in Hikma Pharmaceuticals. This rating has held steady since May 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/10/2025Berenberg BankReiterated RatingBuyGBX 2,560
3/7/2025JPMorgan Chase & Co.Reiterated RatingOverweight
1/29/2025Berenberg BankBoost TargetBuyGBX 2,400 ➝ GBX 2,560
9/2/2024Berenberg BankUpgradeBuyGBX 2,100 ➝ GBX 2,400
8/12/2024Berenberg BankBoost TargetHoldGBX 2,000 ➝ GBX 2,100
6/18/2024Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 2,750
5/7/2024BarclaysReiterated RatingEqual WeightGBX 2,000
4/25/2024Berenberg BankReiterated RatingHoldGBX 2,000
4/8/2024BarclaysReiterated RatingEqual WeightGBX 2,000
2/26/2024Berenberg BankBoost TargetHoldGBX 1,960 ➝ GBX 2,000
11/13/2023Royal Bank of CanadaReiterated RatingSector PerformGBX 2,150
10/16/2023JPMorgan Chase & Co.Reiterated RatingOverweight
10/3/2023CitigroupReiterated RatingBuy
7/12/2023BarclaysBoost TargetEqual WeightGBX 1,700 ➝ GBX 1,800
5/22/2023Jefferies Financial GroupBoost TargetBuyGBX 2,080 ➝ GBX 2,125
5/3/2023BarclaysReiterated RatingEqual WeightGBX 1,700
4/12/2023Jefferies Financial GroupReiterated RatingBuyGBX 2,080
3/9/2023JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,100
3/1/2023Royal Bank of CanadaBoost TargetOutperformGBX 1,750 ➝ GBX 1,950
2/24/2023Berenberg BankBoost TargetHoldGBX 1,440 ➝ GBX 1,740
2/24/2023BarclaysBoost TargetEqual WeightGBX 1,650 ➝ GBX 1,700
2/14/2023JPMorgan Chase & Co.Reiterated RatingOverweight
1/31/2023CitigroupReiterated RatingBuyGBX 1,920
12/5/2022BarclaysReiterated RatingEqual WeightGBX 1,350
12/1/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/3/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/1/2022BarclaysReiterated RatingEqual WeightGBX 1,400
10/4/2022Berenberg BankReiterated RatingHoldGBX 1,440
9/30/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/31/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/11/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,900 ➝ GBX 1,760
8/5/2022BarclaysDowngradeEqual WeightGBX 2,250 ➝ GBX 1,750
8/2/2022BarclaysReiterated RatingOverweightGBX 2,250
7/19/2022BarclaysLower TargetOverweightGBX 2,500 ➝ GBX 2,250
7/4/2022BarclaysReiterated RatingOverweightGBX 2,500
6/1/2022BarclaysReiterated RatingOverweightGBX 2,500
5/25/2022JPMorgan Chase & Co.DowngradeNeutralGBX 2,900 ➝ GBX 1,900
5/24/2022BarclaysReiterated RatingOverweightGBX 2,500
5/11/2022Morgan StanleyReiterated RatingEqual Weight
5/9/2022BarclaysReiterated RatingOverweightGBX 2,800
4/29/2022BarclaysReiterated RatingOverweightGBX 2,800
4/14/2022BarclaysReiterated RatingOverweightGBX 2,800
4/4/2022BarclaysReiterated RatingOverweightGBX 2,800
3/15/2022BarclaysReiterated RatingOverweightGBX 2,800
3/7/2022BarclaysReiterated RatingOverweightGBX 2,800
3/3/2022Morgan StanleyDowngradeEqual WeightGBX 2,800 ➝ GBX 2,300
2/21/2022BarclaysReiterated RatingOverweightGBX 2,800
2/9/2022Morgan StanleyReiterated RatingOverweight
2/9/2022BarclaysLower TargetOverweightGBX 3,000 ➝ GBX 2,800
1/24/2022BarclaysReiterated RatingOverweightGBX 7,000
1/17/2022JPMorgan Chase & Co.Reiterated RatingOverweight
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/17/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/1/2021CitigroupReiterated RatingBuyGBX 2,880
10/20/2021BarclaysBoost TargetOverweightGBX 2,900 ➝ GBX 3,000
9/2/2021BarclaysBoost TargetOverweightGBX 2,800 ➝ GBX 2,900
7/19/2021BarclaysReiterated RatingOverweightGBX 2,800
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
2/1/2021CitigroupReiterated RatingBuy
9/2/2020CitigroupReiterated RatingBuy
7/30/2020Peel HuntBoost TargetBuyGBX 2,380 ➝ GBX 2,860
7/7/2020Morgan StanleyUpgradeOverweightGBX 2,200 ➝ GBX 2,600
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/22/2020Peel HuntReiterated RatingBuy
4/30/2020Peel HuntReiterated RatingBuy
4/28/2020BarclaysBoost TargetEqual WeightGBX 1,950 ➝ GBX 2,200
4/24/2020The Goldman Sachs GroupDowngradeNeutralGBX 2,200 ➝ GBX 2,400
4/24/2020Peel HuntReiterated RatingBuy
4/3/2020CitigroupBoost TargetBuyGBX 2,150 ➝ GBX 2,500
4/2/2020JPMorgan Chase & Co.UpgradeOverweightGBX 1,850 ➝ GBX 2,400
4/2/2020Peel HuntUpgradeBuyGBX 1,990 ➝ GBX 2,380
3/31/2020Peel HuntReiterated RatingHold
(Data available from 3/27/2020 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2024
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2025
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2025

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Hikma Pharmaceuticals logo
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 670 (as of 31 December 2021) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 7 R&D centres and 8,700+ employees worldwide.
Read More

Today's Range

Now: GBX 1,987
Low: 1,978
High: 2,012

50 Day Range

MA: GBX 2,178.08
Low: 1,986
High: 2,339.29

52 Week Range

Now: GBX 1,987
Low: 1,750
High: 2,360

Volume

195,553 shs

Average Volume

1,846,854 shs

Market Capitalization

£5.51 billion

P/E Ratio

19.50

Dividend Yield

2.65%

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Berenberg Bank, Deutsche Bank Aktiengesellschaft, and JPMorgan Chase & Co..
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,436.67, suggesting a possible upside of 22.6%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting HIK will reach GBX 2,750 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of GBX 2,000 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

Other companies that are similar to Hikma Pharmaceuticals include HUTCHMED, Indivior, Amryt Pharma, Alliance Pharma and Allergy Therapeutics. Learn More about companies similar to Hikma Pharmaceuticals.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.